AI Engines For more Details: Perplexity Kagi Labs You
Antibacterial Activity: Sulfamonomethoxine acts by inhibiting the growth and reproduction of susceptible bacteria. It interferes with the synthesis of dihydrofolic acid, a precursor to folate, which is essential for bacterial DNA synthesis and replication. By blocking this pathway, sulfamonomethoxine effectively suppresses bacterial growth and helps to control infections.
Wide Spectrum: Sulfamonomethoxine exhibits a broad spectrum of antibacterial activity against both gram-positive and gram-negative bacteria. It is effective against various bacterial pathogens commonly found in animals, including Escherichia coli, Salmonella spp., Pasteurella spp., Haemophilus spp., Streptococcus spp., and Staphylococcus spp., among others.
Treatment of Bacterial Infections: Sulfamonomethoxine is used in the treatment of bacterial infections affecting different organ systems in animals, including respiratory tract infections, gastrointestinal infections, urinary tract infections, skin and soft tissue infections, and systemic infections. It can be administered orally or parenterally, depending on the severity and location of the infection.
Prevention of Infections: In addition to therapeutic use, sulfamonomethoxine may also be employed for prophylactic purposes to prevent the occurrence or recurrence of bacterial infections in animals, particularly in high-risk situations such as during periods of stress, transportation, or exposure to other animals carrying infectious agents.
Dosage and Administration: The dosage and administration of sulfamonomethoxine may vary depending on the species of animal being treated, the type and severity of the infection, and other factors such as body weight, age, and renal function. It is typically administered orally as a solution, suspension, or bolus, or via injection (intramuscular or subcutaneous) as directed by a veterinarian.
Adverse Effects: While sulfamonomethoxine is generally well tolerated by animals when used appropriately, adverse effects such as gastrointestinal disturbances (e.g., diarrhea, vomiting), allergic reactions (e.g., skin rash, itching, facial swelling), and rare instances of drug toxicity (e.g., hematological abnormalities, hepatotoxicity) may occur in some individuals. Hypersensitivity reactions are possible, particularly in animals with a history of sulfonamide allergy.
Contraindications: Sulfamonomethoxine should be used with caution in animals with known hypersensitivity to sulfonamide antibiotics or a history of adverse reactions. It is not recommended for use in certain animal species (e.g., horses, ruminants) or under specific conditions (e.g., pregnancy, lactation) without veterinary guidance.
Withdrawal Period: In food-producing animals, it is important to observe any required withdrawal periods specified on the product label or by regulatory authorities to ensure that residues of sulfamonomethoxine are not present in edible tissues or products (e.g., meat, milk, eggs) beyond safe levels.
Veterinary Supervision: Sulfamonomethoxine should be used under the guidance and supervision of a licensed veterinarian who can provide appropriate diagnosis, treatment recommendations, and monitoring of the animal's response to therapy.
Rank | Probiotic | Impact |
---|---|---|
genus | Bifidobacterium | Reduces |
species | Akkermansia muciniphila | Reduces |
species | Bacteroides uniformis | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Parabacteroides distasonis | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
Acne | 0.6 | 0.6 | 0 |
ADHD | 4.8 | 0.9 | 4.33 |
Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
Allergic Rhinitis (Hay Fever) | 3.2 | 2.2 | 0.45 |
Allergies | 5.5 | 2.8 | 0.96 |
Allergy to milk products | 1.9 | 1.6 | 0.19 |
Alopecia (Hair Loss) | 1 | 1 | |
Alzheimer's disease | 5.5 | 5.9 | -0.07 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.6 | 1 | 2.6 |
Ankylosing spondylitis | 3.6 | 1.5 | 1.4 |
Anorexia Nervosa | 1.4 | 2.8 | -1 |
Antiphospholipid syndrome (APS) | 1.5 | 1.5 | |
Asthma | 4.7 | 3.3 | 0.42 |
Atherosclerosis | 1.7 | 2.1 | -0.24 |
Atrial fibrillation | 3.8 | 1.7 | 1.24 |
Autism | 8.7 | 7.6 | 0.14 |
Autoimmune Disease | 1.2 | 0.8 | 0.5 |
Barrett esophagus cancer | 0.3 | 0.3 | 0 |
benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
Biofilm | 1.3 | 1.3 | |
Bipolar Disorder | 1.9 | 1.7 | 0.12 |
Brain Trauma | 0.9 | 1.4 | -0.56 |
Breast Cancer | 0.1 | 0.1 | |
Cancer (General) | 0.6 | 2.1 | -2.5 |
Carcinoma | 3.8 | 2.6 | 0.46 |
Celiac Disease | 2.2 | 3.7 | -0.68 |
Cerebral Palsy | 1.5 | 1.3 | 0.15 |
Chronic Fatigue Syndrome | 4.8 | 4 | 0.2 |
Chronic Kidney Disease | 4.5 | 2.2 | 1.05 |
Chronic Lyme | 0.2 | 0.8 | -3 |
Chronic Obstructive Pulmonary Disease (COPD) | 1.2 | 1.7 | -0.42 |
Chronic Urticaria (Hives) | 1.3 | 1 | 0.3 |
Coagulation / Micro clot triggering bacteria | 1.5 | 1.3 | 0.15 |
Cognitive Function | 3.6 | 1.4 | 1.57 |
Colorectal Cancer | 6.3 | 2.1 | 2 |
Constipation | 1.6 | 0.7 | 1.29 |
Coronary artery disease | 2.5 | 2.3 | 0.09 |
COVID-19 | 8.6 | 10.5 | -0.22 |
Crohn's Disease | 6.9 | 5.4 | 0.28 |
Cushing's Syndrome (hypercortisolism) | 0.4 | -0.4 | |
cystic fibrosis | 0.7 | 1.9 | -1.71 |
d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
deep vein thrombosis | 2.8 | 1.4 | 1 |
Denture Wearers Oral Shifts | 0.5 | 0.5 | |
Depression | 9.9 | 8.3 | 0.19 |
Dermatomyositis | 0.3 | 0.3 | 0 |
Eczema | 1.8 | 1.7 | 0.06 |
Endometriosis | 3 | 2.1 | 0.43 |
Eosinophilic Esophagitis | 0.6 | -0.6 | |
Epilepsy | 2.8 | 2.2 | 0.27 |
erectile dysfunction | 1.7 | 0.3 | 4.67 |
Fibromyalgia | 2.5 | 1.2 | 1.08 |
Functional constipation / chronic idiopathic constipation | 5.2 | 3.7 | 0.41 |
gallstone disease (gsd) | 3.5 | 1.2 | 1.92 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.8 | 1.2 | -0.5 |
Generalized anxiety disorder | 3 | 2.5 | 0.2 |
Glioblastoma | 0.3 | -0.3 | |
Gout | 2.6 | 1 | 1.6 |
Graves' disease | 1.9 | 3.3 | -0.74 |
Gulf War Syndrome | 0.7 | 2.3 | -2.29 |
Halitosis | 0.9 | 0.3 | 2 |
Hashimoto's thyroiditis | 3.5 | 1.6 | 1.19 |
Heart Failure | 3.3 | 1.7 | 0.94 |
hemorrhagic stroke | 1 | 1 | |
Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
High Histamine/low DAO | 0.7 | 0.6 | 0.17 |
hypercholesterolemia (High Cholesterol) | 0.4 | 0.6 | -0.5 |
hyperglycemia | 1.6 | 2.1 | -0.31 |
Hyperlipidemia (High Blood Fats) | 1 | 0.3 | 2.33 |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 4.8 | 5.2 | -0.08 |
Hypothyroidism | 0.4 | 1 | -1.5 |
Hypoxia | 2.7 | 0.3 | 8 |
IgA nephropathy (IgAN) | 1.6 | 3.7 | -1.31 |
Inflammatory Bowel Disease | 6.9 | 7.5 | -0.09 |
Insomnia | 2 | 3.4 | -0.7 |
Intelligence | 1.1 | 0 | 0 |
Intracranial aneurysms | 1.2 | 0.9 | 0.33 |
Irritable Bowel Syndrome | 7.5 | 5.4 | 0.39 |
ischemic stroke | 3 | 1.7 | 0.76 |
Liver Cirrhosis | 6.2 | 4.6 | 0.35 |
Long COVID | 7.2 | 7.4 | -0.03 |
Low bone mineral density | 1.1 | -1.1 | |
Lung Cancer | 1.2 | 1.6 | -0.33 |
Lymphoma | 0.6 | 0.6 | |
Mast Cell Issues / mastitis | 0.9 | 0.9 | 0 |
ME/CFS with IBS | 0.9 | 1.4 | -0.56 |
ME/CFS without IBS | 1.8 | 1.2 | 0.5 |
membranous nephropathy | 0.3 | 0.3 | |
Menopause | 2 | 0.9 | 1.22 |
Metabolic Syndrome | 7.2 | 7.1 | 0.01 |
Mood Disorders | 9.7 | 6.8 | 0.43 |
multiple chemical sensitivity [MCS] | 1.1 | 0.1 | 10 |
Multiple Sclerosis | 5.6 | 3.3 | 0.7 |
Multiple system atrophy (MSA) | 1.1 | 0.7 | 0.57 |
myasthenia gravis | 0.9 | 0.5 | 0.8 |
neuropathic pain | 0.3 | 3 | -9 |
Neuropathy (all types) | 1.1 | 2.6 | -1.36 |
neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.6 | 5.1 | -0.11 |
NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
Obesity | 9.5 | 8.1 | 0.17 |
obsessive-compulsive disorder | 4.6 | 4 | 0.15 |
Osteoarthritis | 2.5 | 1.5 | 0.67 |
Osteoporosis | 2.3 | 1.9 | 0.21 |
pancreatic cancer | 0.6 | 0.3 | 1 |
Parkinson's Disease | 7.4 | 5.3 | 0.4 |
Polycystic ovary syndrome | 5 | 2.6 | 0.92 |
Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
primary biliary cholangitis | 1.2 | 0.9 | 0.33 |
Primary sclerosing cholangitis | 1.4 | 2.4 | -0.71 |
Psoriasis | 2.7 | 2.2 | 0.23 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.6 | 3.4 | 0.94 |
Rosacea | 0.9 | 0.8 | 0.13 |
Schizophrenia | 5.6 | 3.2 | 0.75 |
scoliosis | 0.4 | 0.5 | -0.25 |
Sjögren syndrome | 2.2 | 3 | -0.36 |
Sleep Apnea | 1.9 | 1.8 | 0.06 |
Slow gastric motility / Gastroparesis | 1 | 0.3 | 2.33 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.3 | 0.5 | 1.6 |
Stress / posttraumatic stress disorder | 2.7 | 3.3 | -0.22 |
Systemic Lupus Erythematosus | 3.9 | 1.8 | 1.17 |
Tic Disorder | 1 | 1.2 | -0.2 |
Tourette syndrome | 1.2 | 0.3 | 3 |
Type 1 Diabetes | 3.9 | 3.5 | 0.11 |
Type 2 Diabetes | 8.5 | 7.4 | 0.15 |
Ulcerative colitis | 4 | 5.8 | -0.45 |
Unhealthy Ageing | 4.2 | 2.3 | 0.83 |
Vitiligo | 2.3 | 1.4 | 0.64 |